Effect of penetration enhancers on skin permeation of trazodone hydrochloride from matrix type transdermal formulation through mouse and human cadaver epidermis

Acta Poloniae Pharmaceutica - Drug Research

Volumn 63, Issue 6, 2006, Pages 535-541

  Das, Malay K ^a,b   Bhattacharya, Asokangshu ^a   Ghosal, Saroj K ^a  

^a DIBRUGARH UNIVERSITY   (India)

^b DIBRUGARH UNIVERSITY   (India)

Author keywords

Human cadaver epidermis; Isopropyl myristate; Matrix based transdermal formulations; Mouse epidermis; Penetration enhancers; Trazodone hydrochloride

Indexed keywords

BUTANOL; MYRISTIC ACID ISOPROPYL ESTER; OCTANOL; PALMITIC ACID ISOPROPYL ESTER; TRAZODONE; MYRISTIC ACID DERIVATIVE; PALMITIC ACID DERIVATIVE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DIFFUSION; DRUG EFFECT; DRUG FORMULATION; DRUG PENETRATION; DRUG RETENTION; EPIDERMIS; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; SKIN PENETRATION; STEADY STATE; STRATUM CORNEUM; ADULT; ANIMAL; CHEMISTRY; FEMALE; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; SKIN ABSORPTION;

1-BUTANOL; 1-OCTANOL; ADMINISTRATION, CUTANEOUS; ADULT; ANIMALS; CHEMISTRY, PHARMACEUTICAL; FEMALE; HUMANS; MALE; MICE; MIDDLE AGED; MYRISTATES; PALMITATES; SKIN ABSORPTION; TRAZODONE;

EID: 34248140116     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Gorecki D.K.J., Verbeck R.K.: in Analytical Profile of Drug Substances, Vol. 16, Florey K. Ed., p. 693, Academic Press Inc., London 1987.
2. th Edn., Vol. 1, Goodman L., Gilman A., Rall T.W., Nies A.S., Taylor P. Eds., p. 383, Pergamon Press, Maxwell Macmillan Publishing Corporation, New York 1985.
3. Mihara K., Yasui-Furukori N., Kondo T., Ishida H., Ono S., Ohkubo T., Osanai T., Sugawara K., Otani K., Kaneko S.: Ther. Drug Monit. 24, 563 (2002).
4. Scheuplein R.J., Blank I.H.: J. Invest. Dermatol. 60, 286 (1973).
5. Andertson R.L., Cassidy J.M.: J. Invest. Dermatol. 61, 30 (1973).
6. Barry B.W.: J. Control. Rel. 6, 85 (1987).
7. Tenjarla S.N., Allen R., Borazanil A.: Drug Dev. Ind. Pharm. 20, 49 (1994).
8. Panigrahi L., Ghosal S.K.: Indian J. Pharm. Sci. 64, 79 (2002).
9. Kligman A.M., Christophers E.: Arch. Dermatol. 88, 702 (1963).
10. Swarbrick J., Brown J.: J. Invest. Dermatol. 78, 63 (1982).
11. Santoyo S., Ygartua P.: Eur. J. Pharm. Biopharm. 50, 245 (2000).
12. Moghimi H., Noorani N., Zarghi A.: Iranian J. Pharm. Res. 3, 17 (2004).
13. Mortazavi S.A., Aboofazeli R.: Iranian J. Pharm. Res. 135 (2003).
14. Keshary P.R., Chien Y.W.: Drug Dev. Ind. Pharm. 11, 1213 (1984).
15. Berner B., Mazzenga G.C., Otte J.H., Steffens R.J.: J. Pharm. Sci. 78, 402 (1989).
16. Hayton W.L., Chen T.: J. Pharm. Sci. 71, 820 (1982).
17. Narishetty S.T.K., Panchagnula R.: J. Control. Rel. 95, 367 (2004).
18. Mondol S.C., Bhattacharya M., Ghosal S.K.: Drug Dev. Ind. Pharm. 20, 1933 (1994).
19. Sato K., Sugibayashi K., Morimoto Y.: Int. J. Pharm. 43, 31 (1988).
20. Shah H.S., Tojo K., Chien Y.W.: Drug Dev. Ind. Pharm. 18, 1461 (1992).
21. Blank I.H., McAuliffe D.J.: J. Invest. Dermatol. 85, 522 (1985).
22. Sloan K.B., Koch S.A.M., Siver K.G., Flowers F.P.: J. Invest. Dermatol. 87, 244 (1986).
23. Tsuzuki N., Wong O., Higuchi T.: Int. J. Pharm. 46, 19 (1988).
24. Hori M., Satoh S., Maibach H.I., Guy R.H.: J. Pharm. Sci. 80, 32 (1991).